Raffa Wealth Management, LLC
- SEC CIK
- 0001631073
- Latest filing
- Jul 27, 2026
TEVA holding history
Teva Pharmaceutical Industries Ltd in every 13F filed by Raffa Wealth Management, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
TEVA overviewAll 13F holders of TEVAFull Q2 2026 holdings
- Shares (Q2 2026)
- 38
- Value
- $1.29K
- % of portfolio
- <0.1%
- Quarters held
- 37
- Since Q4 2013
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 38 | $1.29K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2026 | 38 | $1.15K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2025 | 38 | $1.19K | <0.1% | −19−33.3% | Reduced | Holders |
| Q3 2025 | 57 | $1.15K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2025 | 57 | $955 | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2025 | 57 | $876 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2024 | 57 | $1.26K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 57 | $1.03K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 57 | $926 | <0.1% | +57 | New | Holders |
| Q1 2021 | 0 | $0 | 0.0% | −90−100.0% | Sold out | Holders |
| Q4 2020 | 90 | $869 | <0.1% | 00.0% | Unchanged | – |
| Q3 2020 | 90 | $811 | <0.1% | 00.0% | Unchanged | – |
| Q2 2020 | 90 | $1.11K | <0.1% | 00.0% | Unchanged | – |
| Q1 2020 | 90 | $808 | <0.1% | 00.0% | Unchanged | – |
| Q4 2019 | 90 | $882 | <0.1% | 00.0% | Unchanged | – |
| Q3 2019 | 90 | $619 | <0.1% | +90 | New | – |
| Q2 2019 | 0 | $0 | 0.0% | −90−100.0% | Sold out | – |
| Q1 2019 | 90 | $1.41K | <0.1% | −70−43.8% | Reduced | – |
| Q4 2018 | 160 | $2.47K | <0.1% | −180−52.9% | Reduced | – |
| Q3 2018 | 340 | $7.32K | <0.1% | 00.0% | Unchanged | – |
| Q2 2018 | 340 | $8.27K | <0.1% | 00.0% | Unchanged | – |
| Q1 2018 | 340 | $5.81K | <0.1% | 00.0% | Unchanged | – |
| Q4 2017 | 340 | $6.44K | <0.1% | 00.0% | Unchanged | – |
| Q3 2017 | 340 | $5.98K | <0.1% | −150−30.6% | Reduced | – |
| Q2 2017 | 490 | $16.3K | <0.1% | 00.0% | Unchanged | – |
| Q1 2017 | 490 | $15.7K | <0.1% | −39−7.4% | Reduced | – |
| Q4 2016 | 529 | $19.2K | <0.1% | +13+2.5% | Added | – |
| Q3 2016 | 516 | $23.7K | <0.1% | −100−16.2% | Reduced | – |
| Q2 2016 | 616 | $30.9K | <0.1% | +255+70.6% | Added | – |
| Q1 2016 | 361 | $19.3K | <0.1% | 00.0% | Unchanged | – |
| Q4 2015 | 361 | $23.7K | <0.1% | 00.0% | Unchanged | – |
| Q3 2015 | 361 | $20.4K | <0.1% | 00.0% | Unchanged | – |
| Q2 2015 | 361 | $21.3K | <0.1% | 00.0% | Unchanged | – |
| Q1 2015 | 361 | $22.5K | <0.1% | −148−29.1% | Reduced | – |
| Q4 2014 | 509 | $29.3K | <0.1% | +148+41.0% | Added | – |
| Q3 2014 | 361 | $19.4K | <0.1% | +21+6.2% | Added | – |
| Q2 2014 | 340 | $17.8K | <0.1% | 00.0% | Unchanged | – |
| Q1 2014 | 340 | $18.0K | <0.1% | −169−33.2% | Reduced | – |
| Q4 2013 | 509 | $29.3K | <0.1% | – | – | – |
Livermore's 13F data starts with Q4 2013, so Q4 2013 has no change from the previous quarter.